Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* To be clinically healthy~* To have the ability to voluntarily grant your signed informed consent~* To have the willingness to comply with scheduled visits treatment plan and other study procedures~* Women in reproductive age should ensure the continuation (initiated ≥ 30 days prior to the signing of the informed consent) to use a hormonal contraceptive method or intrauterine device during the study period.~* To have a better corrected visual acuity of 20/30 or better in both eyes.~* To have vital signs in normal parameters.~* To have an intraocular pressure between ≥10 and ≤ 21 mmHg.~Exclusion Criteria:~* To be user of ophthalmic topical products of any kind.~* To be user of medicines, or herbal products, by any other route of administration.~* In the case of women: being pregnant, breastfeeding or planning to get pregnant in the study period.~* Having participated in clinical research studies 90 days prior to inclusion in this study.~* Having previously participated in this same study.~* To be a user of contact lenses and can not suspend their use during the study.~* Having initiated the use of hormonal contraceptives or intrauterine devices, 30 days prior to inclusion in the present study.~* To have a history of any chronic degenerative disease.~* Having inflammatory or infectious disease, active at the time of admission to the study.~* Having injuries or unresolved injuries at the time of admission to the study.~* Having a history of any type of eye surgery.~* Having undergone surgical procedures, not ophthalmological, in the last 3 months.~* To be or to have an immediate family member (for example: spouse, parent / legal guardian, brother or child) who is part of the research site staff or the sponsor who participates directly in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Lagricel® Ofteno Multidose (Type: EXPERIMENTAL): Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
- Lagricel® Ofteno Single dose (Type: ACTIVE_COMPARATOR): Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia

Based on this trial design, predict the completion outcome and termination type (if applicable).